The earnings call presented a strong start to 2025 with significant revenue growth and improvements in dispensary segment performance, gross profit, and SG&A reduction. However, challenges remain with adjusted EBITDA loss, net loss, and the revenue impact from outsourcing the clinical trials program. Despite these challenges, the overall trajectory and strategic initiatives indicate a focus on future profitability.

Company Guidance -

Q1 2025

In the first quarter of 2025, The Oncology Institute reported a 10% increase in revenue compared to the same period in the previous year, with total revenue reaching $104.4 million. The company's retail Pharmacy and Dispensary business significantly contributed to this growth, generating $49.3 million in revenue and over $9 million in gross profit, representing a 20% year-over-year increase. The fee-for-service business also saw growth, with a 9% increase quarter-over-quarter and a 2% increase year-over-year. Additionally, the company signed new capitated contracts in Florida, California, and Nevada, adding over 80,000 lives and projecting approximately $50 million in new annualized revenue. The company reported an adjusted EBITDA loss of $5.1 million, aligning with the upper end of their guidance, and achieved a gross profit of $17.2 million, a 44.1% increase from the previous year. The company anticipates continuing this positive trajectory towards profitability and cash flow positivity by the end of 2025, supported by strategic market expansions and operational efficiencies.

Revenue Growth

Revenue for Q1 2025 increased by 10% versus the prior year period, reaching $104.4 million.

Dispensary Segment Performance

The Dispensary segment grew by 24.2%, contributing $49.3 million in revenue and over $9 million in gross profit in Q1.

Capitated Contract Wins

New capitated contract wins added over 80,000 lives in the first quarter with projected new revenue of approximately $50 million on an annualized basis.

Gross Profit Improvement

Gross profit in Q1 of 2025 was $17.2 million, an increase of 44.1% compared to Q1 of 2024.

SG&A Reduction

SG&A, including depreciation and amortization, was $27.2 million in Q1 of 2025, a 9% decline compared to Q1 of 2024.

Debt Reduction and Capital Raise

Executed a partial paydown of convertible preferred debt of $20 million and a capital raise that added $16 million back to the balance sheet.

Oncology Institute (TOI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TOI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.09 / -	-0.17	―	―	―
May 14, 2025	2025 (Q1)	- / -0.21	-0.22	4.55% (+0.01)	―
Mar 24, 2025	2024 (Q4)	- / -0.14	-0.21	33.33% (+0.07)	―
Nov 13, 2024	2024 (Q3)	- / -0.18	-0.19	5.26% (+0.01)	―
Aug 13, 2024	2024 (Q2)	-0.09 / -0.17	-0.19	10.53% (+0.02)	―
May 14, 2024	2024 (Q1)	-0.12 / -0.22	-0.33	33.33% (+0.11)	―
Mar 27, 2024	2023 (Q4)	-0.11 / -0.21	-0.16	-31.25% (-0.05)	―
Nov 08, 2023	2023 (Q3)	-0.13 / -0.19	-0.17	-11.76% (-0.02)	―
Aug 08, 2023	2023 (Q2)	-0.17 / -0.19	-0.09	-111.11% (-0.10)	―
May 10, 2023	2023 (Q1)	- / -0.33	0.253	-230.43% (-0.58)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TOI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$2.37	$3.04	+28.27%
Mar 24, 2025	$1.00	$1.24	+24.00%
Nov 13, 2024	$0.26	$0.24	-7.69%
Aug 13, 2024	$0.55	$0.45	-18.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Oncology Institute, Inc. (TOI) report earnings?

Oncology Institute, Inc. (TOI) is schdueled to report earning on Aug 12, 2025, After Close (Confirmed).

What is Oncology Institute, Inc. (TOI) earnings time?

Oncology Institute, Inc. (TOI) earnings time is at Aug 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TOI EPS forecast?

TOI EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing